Home > Insider Trading > Filing (0000950142-14-001812)

Filing Details

Accession Number:: 0000950142-14-001812
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-09-04 20:29:56
Reporting Period:: 2014-09-02

Filing Date:: 2014-09-04
Accepted Time:: 2014-09-04 20:29:56
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1415336	Zeltiq Aesthetics Inc	ZLTQ	Electromedical & Electrotherapeutic Apparatus (3845)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1172252	N Andrew Schiff	888 Seventh Avenue 30Th Floor New York NY 10106		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-09-02	30,000	$0.00	31,152	No	4	X	Direct
Common Stock	Acquisiton	2014-09-02	5,165	$0.00	36,317	No	4	X	Direct
Common Stock	Disposition	2014-09-02	35,165	$22.55	1,152	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	X	Direct
No	4	X	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (Right to Buy)	Acquisiton	2014-09-02	30,000	$0.00	30,000	$6.34
Common Stock	Stock Options (Right to Buy)	Acquisiton	2014-09-02	5,165	$0.00	5,165	$5.06

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2014-06-19	2023-06-18	No	4	X	Direct
4,371	2013-06-14	2022-06-14	No	4	X	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,597,742	Indirect	By Aisling Capital III, L.P.

Footnotes

These shares were sold by our broker pursuant to instructions given to our broker by the reporting person on July 31, 2014, pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.16 to $23.33, inclusive. The reporting person undertakes to provide to Zeltiq Aesthetics, Inc., any security holder of Zeltiq Aesthetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the preceding sentence.
Includes 87 shares of Common Stock held by a trust for the benefit of Mr. Schiff's children.
These stock options are held by Mr. Schiff for the benefit of Aisling Capital LLC. Mr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
The shares are directly held by Aisling Capital III, LP ("Aisling") and are indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III, LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Andrew Schiff is a member of the Board of Directors of Zeltiq Aesthetics, Inc.
Issued pursuant to the 2011 Equity Incentive Plan of the Issuer.
As of the date of this report, 5,165 shares subject to the option have vested and the remainder will vest in 22 ratable monthly installments hereafter, subject to the Reporting Person's continued service with the Issuer.
These stock options were exercised by our broker, pursuant to instructions given to our broker by the reporting person on July 31, 2014, pursuant to a Rule 10b5-1 trading plan.